FDA backs Corbus (NASDAQ: CRBP) CRB-701 registrational plans in HNSCC and cervical cancer

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. announced broad alignment with the U.S. Food and Drug Administration on the registration path for CRB-701, its Nectin-4–targeting antibody drug conjugate, in second-line head and neck squamous cell carcinoma and cervical cancer. The agreed plans call for single, randomized controlled registrational studies in each indication, comparing CRB-701 to physicians’ choice chemotherapy or chemotherapy/Tivdak, with potential accelerated approval based on objective response rate and potential full approval based on overall survival.

The FDA has granted two Fast Track designations to CRB-701 in head and neck squamous cell carcinoma and cervical cancer. Updated Phase 1/2 monotherapy data will be presented at ASCO 2026, and the company anticipates reporting first-line HNSCC combination data with Keytruda in Q4 2026. Corbus expects to initiate a registrational study in second-line HNSCC in mid-2026. The company also disclosed that Chief Medical Officer Dr. Dominic Smethurst will step down effective June 30, 2026, as it adds new senior leaders for the next development phase.

Positive

Regulatory alignment and Fast Track status for CRB-701: The company secured broad alignment with the FDA on single, randomized registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, and the FDA has granted two Fast Track designations in these indications, supporting a clearer, potentially expedited development path.

Negative

None.

Insights

FDA alignment and Fast Track status move CRB-701 into registrational-stage planning despite an upcoming CMO transition.

Corbus Pharmaceuticals now has FDA alignment on single, randomized registrational studies for CRB-701 in second-line head and neck squamous cell carcinoma and cervical cancer, using objective response rate for potential accelerated approval and overall survival for potential full approval. The FDA has also granted two Fast Track designations in these indications.

Planned data milestones include updated Phase 1/2 monotherapy results at the 2026 ASCO Annual Meeting and combination data with Keytruda in first-line HNSCC in Q4 2026. The company expects to start a registrational study in second-line HNSCC in mid-2026, marking a shift toward late-stage development.

Chief Medical Officer Dr. Dominic Smethurst will leave on June 30, 2026, while the company plans to add senior leaders for this next phase. Overall, the regulatory clarity and Fast Track designations represent a positive development for CRB-701’s advancement, with execution now dependent on successful study initiation and forthcoming clinical data.

8-K Event Classification

4 items: 5.02, 7.01, 8.01, 9.01

4 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Fast Track designations: 2 designations ASCO 2026 presentation window: May 29 – June 2, 2026 Planned HNSCC registrational study start: mid-2026 +3 more

6 metrics

Fast Track designations 2 designations CRB-701 in head and neck squamous cell carcinoma and cervical cancer

ASCO 2026 presentation window May 29 – June 2, 2026 Updated CRB-701 Phase 1/2 monotherapy data in HNSCC and cervical cancer

Planned HNSCC registrational study start mid-2026 Initiation of CRB-701 registrational study in second-line HNSCC

Keytruda combo data timing Q4 2026 CRB-701 plus Keytruda in first-line HNSCC patients

CMO resignation effective date June 30, 2026 Chief Medical Officer Dr. Dominic Smethurst stepping down

Resignation notice date April 1, 2026 Date Corbus was notified of Dr. Smethurst’s resignation

Key Terms

accelerated approval, objective response rate (ORR), overall survival (OS), antibody drug conjugate (ADC), +2 more

6 terms

accelerated approval regulatory

"with potential accelerated approval using objective response rate (ORR) as the primary endpoint"

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

objective response rate (ORR) medical

"potential accelerated approval using objective response rate (ORR) as the primary endpoint"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors shrink by a pre-set amount for a minimum time, counting both complete disappearance and meaningful partial shrinkage. Investors watch ORR because it gives an early, quantitative signal that a treatment is having a direct effect on disease—like the percent of people whose fever drops after taking a medicine—which can influence expectations for later trial success, regulatory approval, and market potential.

overall survival (OS) medical

"potential full approval granted on overall survival (OS) benefit"

Overall survival (OS) is the length of time from the start of a treatment or clinical study until death from any cause, essentially measuring how long patients live after a therapy begins. Investors watch OS because it is the most direct evidence a treatment extends life; stronger OS results can drive regulatory approvals, wider use and higher revenue expectations, much like sales figures proving a product actually works.

antibody drug conjugate (ADC) medical

"next-generation, highly stable Nectin-4 targeting antibody drug conjugate ("ADC")"

A antibody drug conjugate (ADC) is a targeted medicine that combines an antibody, which seeks out specific cells, with a potent drug payload so the treatment delivers its toxic effect directly to diseased cells while sparing most healthy tissue—think of a guided missile carrying a small explosive. Investors care because ADCs can offer breakthrough therapies with high market value, but their worth depends heavily on clinical trial results, manufacturing complexity and regulatory approval, which create both upside and risk.

Fast Track designations regulatory

"The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer."

A fast track designation is a regulatory status granted to a drug or therapy intended to treat a serious condition with unmet medical need, which gives the developer access to expedited interactions and review procedures with regulators. For investors, it’s like an express lane: it can shorten development and review timelines and reduce regulatory uncertainty, potentially speeding a product to market—but it does not guarantee approval or commercial success.

Nectin-4 medical

"CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4"

A cell-surface protein that helps neighboring cells stick together and communicate; it is normally present during development but can become abundant on certain cancer cells. Investors pay attention because high levels make it a useful biomarker and a direct target for cancer therapies and diagnostic tests—similar to a distinctive flag on a building that lets a targeted treatment or test find and act on diseased tissue—affecting drug value, regulatory reviews, and market potential.

Understanding 8-K Material Events →

04/07/2026 - 08:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): April 1, 2026

    

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-37348	46-4348039
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

500 River Ridge Drive
Norwood, Massachusetts		02062
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (617) 963-0100

    

     Not Applicable

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	CRBP	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2026, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) was notified by Dominic Smethurst, the Company’s Chief Medical Officer, of his resignation, effective June 30, 2026.

Item 7.01 Regulation FD Disclosure.

On April 7, 2026, the Company issued a press release announcing broad alignment with the U.S. Food and Drug Administration (“FDA”) on the registration path for CRB-701, the Company’s next-generation, highly stable Nectin-4 targeting antibody drug conjugate (“ADC”), in second-line head and neck squamous cell carcinoma (“HNSCC”) and cervical cancer, with registrational study designs intended to support potential accelerated approval. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1, is being furnished to the Securities and Exchange Commission (the “SEC”), and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Item 8.01 Other Events.

On April 7, 2026, the Company announced broad alignment with the FDA on the registration path for CRB-701, the Company’s next-generation, highly stable Nectin-4 targeting ADC, in HNSCC and cervical cancer.

The agreed upon second-line registrational study designs for CRB-701 include:

•

HNSCC: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians’ choice chemotherapy with potential accelerated approval using objective response rate (ORR) as the primary endpoint and potential full approval granted on overall survival (OS) benefit.

•

Cervical cancer: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians’ choice of chemotherapy or Tivdak® with potential accelerated approval using ORR as the primary endpoint and potential full approval granted on OS benefit.

•

Continued interactions with the FDA planned to finalize the protocols and statistical analysis plans for the registrational studies.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:


Exhibit No.		Description
99.1		Press Release dated April 7, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			Corbus Pharmaceuticals Holdings, Inc.

Date:	April 7, 2026	By:	/s/ Yuval Cohen
			Name: Yuval Cohen Title: Chief Executive Officer

Exhibit 99.1

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer

Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026

Dr. Dominic Smethurst to step down as Corbus’ Chief Medical Officer on June 30, 2026

Norwood, MA, April 7, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced broad alignment with the U.S. Food and Drug Administration (FDA) on the registration path for CRB-701, the Company’s next-generation, highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical cancer. Corbus also announced that Dr. Dominic Smethurst, MA, MRCP is stepping down from his role as Chief Medical Officer; his last day with the company will be June 30, 2026.

The agreed upon second-line registrational study designs for CRB-701 include:

•

Continued interactions with the FDA planned to finalize the protocols and statistical analysis plans for the registrational studies.

Updated clinical data from the Phase 1/2 study of CRB-701 in both HNSCC and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 29 – June 2 in Chicago. Data will include clinical response durability as well as HNSCC patient subgroup analysis. Corbus previously presented dose optimization data from the study, including encouraging efficacy and safety findings, at the 2025 European Society for Medical Oncology Congress (ESMO 2025). The company also anticipates reporting data with CRB-701 in combination with Keytruda® in first-line HNSCC patients in Q4 2026 to support potential further registration-enabling trials.

“We’re pleased to share this important regulatory update as we continue to progress CRB-701 as a novel oncology therapeutic to address unmet medical needs for patients. We look forward to sharing updated monotherapy data on CRB-701 at ASCO and expect to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Dr. Cohen continued, “This milestone marks an important transition from clinical proof of concept to pending late-stage registrational development and the potential for regulatory submission of CRB-701. This year we will be adding several key new senior leaders to best prepare us for this critical next phase. We are very grateful for Dr. Smethurst’s contributions to advance our pipeline programs through early development, well positioning Corbus for continued success.”

About CRB-701
CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown

risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACTS:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:

Liz Melone

Founder & Principal

Melone Communications, LLC

liz@melonecomm.com

Source: View Original Filing on SEC EDGAR

FAQ

What did Corbus Pharmaceuticals (CRBP) announce regarding the FDA and CRB-701?

Corbus announced broad alignment with the FDA on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer. Single, randomized registrational studies are planned, aiming for potential accelerated approval based on objective response rate and potential full approval based on overall survival.

What cancers is CRB-701 targeting in Corbus Pharmaceuticals’ 8-K disclosure?

CRB-701 targets Nectin-4–expressing tumors, with a focus on second-line head and neck squamous cell carcinoma and cervical cancer. The planned registrational trials compare CRB-701 against physicians’ choice chemotherapy or chemotherapy/Tivdak, with endpoints designed to support potential accelerated and subsequent full approvals.

How are the planned CRB-701 registrational studies in HNSCC and cervical cancer designed?

Each indication will use a single, randomized controlled study comparing CRB-701 to physicians’ choice regimens. Accelerated approval would be based on objective response rate as the primary endpoint, while potential full approval would be supported by demonstrating an overall survival benefit in these trials.

When will Corbus present new CRB-701 clinical data and what will be shown?

Updated CRB-701 monotherapy data from the Phase 1/2 study in head and neck squamous cell carcinoma and cervical cancer will be presented at the 2026 ASCO Annual Meeting, May 29–June 2 in Chicago, including clinical response durability and subgroup analysis in head and neck squamous cell carcinoma patients.

What future CRB-701 data does Corbus Pharmaceuticals expect beyond ASCO 2026?

Corbus anticipates reporting data for CRB-701 combined with Keytruda in first-line head and neck squamous cell carcinoma patients in Q4 2026. These data are intended to support potential further registration-enabling trials and follow earlier monotherapy findings shared at prior oncology conferences.

What leadership change did Corbus Pharmaceuticals disclose in this 8-K?

Corbus reported that Chief Medical Officer Dr. Dominic Smethurst notified the company of his resignation, effective June 30, 2026. The company plans to add several key new senior leaders during 2026 to prepare for late-stage development and potential regulatory submission of CRB-701.

What special regulatory designations has CRB-701 received from the FDA?

The FDA has granted two Fast Track designations to CRB-701 in head and neck squamous cell carcinoma and cervical cancer. Fast Track status is intended to facilitate development of therapies that address serious conditions and may improve the efficiency of regulatory interactions and review.

Filing Exhibits & Attachments

2 documents

Press Releases

EX-99.1 EX-99.1 24.6 KB